title: Prophylaxis and treatment of cytomegalovirus infection postrenal transplantation in two Madrid units.
abstract: BACKGROUND
  Complete prevention of cytomegalovirus (CMV) disease continues to be an unresolved problem in renal transplantation.
  
  
  METHODS
  From January 2005 to May 2006, we implemented a protocol for early detection and preemptive treatment of CMV infection as detected by antigenemia or polymerase chain reaction determined every 2 weeks during the first 3 months posttransplant and monthly thereafter. Prophylaxis was given to all CMV-negative patients who received CMV-positive kidneys and to those who received polyclonal or monoclonal antibody induction therapy.
  
  
  RESULTS
  Among 100 transplants, 15 subjects received prophylaxis due to poly- or monoclonal antibody induction and/or negative recipient serology using a mean valgancyclovir dose of 485 +/- 276 mg/d for an average duration of 129 days. After completion of the prophylaxis four patients (26.6%) required preemptive therapy for asymptomatic virus reactivation; the mean dose of drug in these patients had been 450 +/- 275.56 mg, with a treatment time that was significantly shorter than those not suffering reactivation (91.75 vs 143.45 days). In addition, preemptive therapy was given for virus reactivation in seven patients, for illness with mild viral syndrome in two, with moderate illness and positive pretransplantation serology in one. The average treatment time was 79 days and the mean dose was 375 mg.
  
  
  CONCLUSIONS
  In those not at risk, CMV infections occurred among 11.7% of patients in our early detection program. Prophylaxis for at-risk patients should continue for more than 3 months to prevent reactivation.
authors.affiliation: Nephrology Department, Hospital Ramón y Cajal, Madrid, Spain. afernandezr.hrc@salud.madrid.org
authors.forename: A
authors.initials: A
authors.lastname: Fernández
authors.forename: Y
authors.initials: Y
authors.lastname: Amezquita
authors.forename: E
authors.initials: E
authors.lastname: Fernández-Tagarro
authors.forename: F
authors.initials: F
authors.lastname: Escuin
authors.forename: C
authors.initials: C
authors.lastname: Jiménez
authors.forename: R
authors.initials: R
authors.lastname: Sánchez Villanueva
authors.forename: C
authors.initials: C
authors.lastname: Galeano
authors.forename: J
authors.initials: J
authors.lastname: Pascual
authors.forename: R
authors.initials: R
authors.lastname: Marcén
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D001774:Blood Chemical Analysis; D003587:Cytomegalovirus / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000009:adverse effects*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D013030:Spain; D000077562:Valganciclovir; D019562:Viral Load; D014775:Virus Activation
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir